Jeffrey Dayno on clinical practice
From Jeffrey Dayno, MD, Highlights Harmony Biosciences' Commitment to Patients, Passion and Purpose · · Paragon Biosciences
“I've tried to bring an understanding of the dynamic between clinical practice and what we do in the industry, going back to drug development and working towards the target product profile, understanding the clinical relevance of where that product fits into therapy.”
On , Jeffrey Dayno, President, Chief Executive Officer & Director at HARMONY BIOSC HOLD INC, spoke about clinical practice during Jeffrey Dayno, MD, Highlights Harmony Biosciences' Commitment to Patients, Passion and Purpose on Paragon Biosciences.
About Jeffrey Dayno
Jeffrey Dayno, MD, the chief medical officer at Harmony Biosciences, described the company as a commercial-stage pharmaceutical firm focused on developing and commercializing therapies for orphan rare neurological diseases. In a September 2023 appearance, Dayno stated that his responsibilities include overseeing the clinical development team, clinical operations, regulatory affairs, medical affairs, and pharmacovigilance. He said that these groups work together to support clinical development programs and interact with the commercial team when preparing for product approvals and launches. Dayno said that what excites him in his role is the "passion and energy and commitment" at Harmony, which he said centers on "patience, passion, and purpose" regarding patients with orphan rare neurological disorders. He noted that he has tried to bring an understanding of the dynamic between clinical practice and the pharmaceutical industry into his work, emphasizing the importance of healthcare professionals making treatment decisions with information from sales representatives. Dayno added that he is focused on the "big picture" strategic vision for drug development and medical strategy in support of commercial strategy, including working toward submitting a new drug application to the FDA and preparing for product launches.